Animal test reveals new potential Parkinson's drug treatment
A new Parkinson's disease drug could soon be incorporated into long term care plans, following a promising breakthrough in an animal study.
This new treatment, known as platelet-derived growth factor-BB (PDGF-BB), was shown to restore brain function in rodents.
Researchers involved in the study note that few treatments for the condition restore function for extended periods.
The rats behaviour was observed as being normalised for a period of ten weeks after the treatment.
Lead researcher Anders Haegerstrand, chief scientific officer at NeuroNova AB, said: "In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration.
"Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."
In addition to drugs, physical activity is recommended for Parkinson's. Low intensity treadmill exercise was recently highlighted as one of the best ways to improve walking in Parkinson's patients, according to researchers from the Maryland School of Medicine in Baltimore.